Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Personalis Inc (PSNL)

Personalis Inc (PSNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 715,316
  • Shares Outstanding, K 88,804
  • Annual Sales, $ 84,610 K
  • Annual Income, $ -81,280 K
  • EBIT $ -81 M
  • EBITDA $ -73 M
  • 60-Month Beta 1.98
  • Price/Sales 9.84
  • Price/Cash Flow N/A
  • Price/Book 3.84

Options Overview Details

View History
  • Implied Volatility 187.20% (-130.22%)
  • Historical Volatility 98.42%
  • IV Percentile 58%
  • IV Rank 18.85%
  • IV High 556.11% on 04/15/25
  • IV Low 101.48% on 12/02/25
  • Expected Move (DTE 12) 2.47 (30.69%)
  • Put/Call Vol Ratio 2.13
  • Today's Volume 197
  • Volume Avg (30-Day) 165
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 2,963
  • Open Int (30-Day) 3,307
  • Expected Range 5.59 to 10.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 1
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -34.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.27 +10.80%
on 02/05/26
11.50 -29.96%
on 01/22/26
-1.09 (-11.97%)
since 01/06/26
3-Month
6.63 +21.58%
on 11/07/25
11.50 -29.96%
on 01/22/26
+0.87 (+12.11%)
since 11/06/25
52-Week
2.83 +184.63%
on 04/07/25
11.50 -29.96%
on 01/22/26
+2.90 (+56.10%)
since 02/06/25

Most Recent Stories

More News
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of...

PSNL : 8.06 (+8.63%)
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health,...

PSNL : 8.06 (+8.63%)
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Trackerâ„¢

New NeXT Personal® extension empowers clinicians to identify emerging resistance and therapeutically targetable mutations during disease monitoring and surveillance

PSNL : 8.06 (+8.63%)
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in cancer care...

ONCY : 0.8859 (+5.89%)
PYXS : 1.5100 (-1.95%)
PSNL : 8.06 (+8.63%)
NBP : 3.70 (+11.11%)
TOI : 2.61 (+6.53%)
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms initial 2025 projections Strong cash position...

PSNL : 8.06 (+8.63%)
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research , a journal of the American...

PSNL : 8.06 (+8.63%)
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark...

PSNL : 8.06 (+8.63%)
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37 th Annual Healthcare...

PSNL : 8.06 (+8.63%)
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence...

PSNL : 8.06 (+8.63%)
Personalis: Q3 Earnings Snapshot

Personalis: Q3 Earnings Snapshot

PSNL : 8.06 (+8.63%)

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

3rd Resistance Point 9.01
2nd Resistance Point 8.63
1st Resistance Point 8.34
Last Price 8.06
1st Support Level 7.67
2nd Support Level 7.29
3rd Support Level 7.01

See More

52-Week High 11.50
Fibonacci 61.8% 8.19
Last Price 8.06
Fibonacci 50% 7.16
Fibonacci 38.2% 6.14
52-Week Low 2.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar